Immunoblotting analysis revealed that treatment with rVP1 (0.4 μM) for 24 h attenuated EMT by upregulating E-cadherin and downregulating vimentin expression levels in A549, H1299 and CL1-5 lung cancer cell lines (Figure 1C). This evidence concerns the gene CLDN3 and lung carcinoma.